Genprex, Inc. (GNPX)Healthcare | Biotechnology | Austin, United States | NasdaqCM
3.67 USD
+0.06
(1.662%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.67 |
Hot Take ↕ | Aug. 22, 2026, 1:09 a.m. EDT
The immediate outlook is severely compromised by a delisting notice and a massive 99.8% cumulative decline over the last seven years, signaling a complete failure of the business model to generate value or sustain operations. While recent headlines highlight positive preclinical data for diabetes therapies, the market has already priced this out, evidenced by the stock trading at a fraction of its book value and generating significant negative free cash flow. The trailing twelve-month earnings are effectively nonexistent, rendering traditional valuation metrics useless, and the lack of any dividend history confirms the company is burning capital rather than returning it. With five consecutive years of negative annual returns and a low-confidence statistical model predicting further downside, there is no safe entry point for a short-term trade, let alone a long-term investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.198112 |
| AutoETS | 0.198579 |
| MSTL | 0.211278 |
| AutoTheta | 0.227390 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.411 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 3,008,332 |
| Trailing P/E | 0.11 |
| Forward P/E | -1.68 |
| Beta | -0.89 |
| Website | https://www.genprex.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.979229 |
| Address1 | 3,300 Bee Cave Road |
| Address2 | Suite 650-227 |
| All Time High | 855,800.0 |
| All Time Low | 3.57 |
| Ask | 4.71 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 555,710 |
| Average Daily Volume3 Month | 172,501 |
| Average Volume | 172,501 |
| Average Volume10Days | 555,710 |
| Beta | -0.888 |
| Bid | 2.63 |
| Bid Size | 2 |
| Book Value | 29.227 |
| City | Austin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.67 |
| Current Ratio | 6.765 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.75 |
| Day Low | 3.6301 |
| Display Name | Genprex |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,596,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -12,145,871 |
| Eps Forward | -2.18 |
| Eps Trailing Twelve Months | 34.43 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.8553 |
| Fifty Day Average Change | -4.1853 |
| Fifty Day Average Change Percent | -0.5327995 |
| Fifty Two Week Change Percent | -97.9229 |
| Fifty Two Week High | 1,210.0 |
| Fifty Two Week High Change | -1,206.33 |
| Fifty Two Week High Change Percent | -0.9969669 |
| Fifty Two Week Low | 3.57 |
| Fifty Two Week Low Change | 0.10000014 |
| Fifty Two Week Low Change Percent | 0.028011246 |
| Fifty Two Week Range | 3.57 - 1210.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,522,330,200,000 |
| Float Shares | 818,717 |
| Forward Eps | -2.18 |
| Forward P E | -1.6834862 |
| Free Cashflow | -10,575,076 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Fullday Change | 0.0600002 |
| Fullday Change Percent | 1.66205 |
| Fullday Price | 3.67 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00215 |
| Held Percent Institutions | 0.01737 |
| Implied Shares Outstanding | 819,709 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,784,160,000 |
| Last Split Factor | 1:22 |
| Long Business Summary | Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive; New York University; UTHealth Houston; and University of Pittsburgh. The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas. |
| Long Name | Genprex, Inc. |
| Market | us_market |
| Market Cap | 3,008,332 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_225557674 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -16,498,565 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,967,346 |
| Open | 3.68 |
| Operating Cashflow | -15,562,704 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 877 774 4679 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.67 |
| Post Market Time | 1,787,954,443 |
| Previous Close | 3.61 |
| Price Hint | 4 |
| Price To Book | 0.12556882 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.471 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0600002 |
| Regular Market Change Percent | 1.66205 |
| Regular Market Day High | 3.75 |
| Regular Market Day Low | 3.6301 |
| Regular Market Day Range | 3.6301 - 3.75 |
| Regular Market Open | 3.68 |
| Regular Market Previous Close | 3.61 |
| Regular Market Price | 3.67 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 53,941 |
| Return On Assets | -0.94461995 |
| Return On Equity | -2.03859 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 819,709 |
| Shares Percent Shares Out | 0.0764 |
| Shares Short | 62,590 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 40,222 |
| Short Name | Genprex, Inc. |
| Short Percent Of Float | 0.0764 |
| Short Ratio | 0.31 |
| Source Interval | 15 |
| State | TX |
| Symbol | GNPX |
| Total Cash | 15,154,203 |
| Total Cash Per Share | 18.487 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 34.43 |
| Trailing P E | 0.10659309 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 33.547794 |
| Two Hundred Day Average Change | -29.877794 |
| Two Hundred Day Average Change Percent | -0.89060384 |
| Type Disp | Equity |
| Volume | 53,941 |
| Website | https://www.genprex.com |
| Zip | 78,746 |